NEW YORK, Sept. 10, 2012 (GLOBE NEWSWIRE) -- Amorcyte, LLC, a subsidiary of NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), today announced a significant expansion in its claims granted to protect the use of CD34+ cells, acquired from blood or bone marrow, to impart a therapeutic benefit to tissue sustaining an ischemic injury. "We received notification that claims granted in the United States have now been granted by the Japanese Patent Office. Additionally, we received recently a Notice of Allowance from the U.S. Patent Office that further expands the scope and protection of our existing CD34+ product patents here in the U.S.," said Andrew Pecora, M.D. FACP CPE, Chief Medical Officer of NeoStem. "Collectively, our newly granted and issued claims will support commercialization of AMR-001 globally, if approved, and afford the potential to broaden the scope of AMR-001's development to include repair of ischemic tissue anywhere in the body."
NeoStem Subsidiary, Amorcyte, Announces Significant Expansion In Its Claims Granted To Protect The Use Of CD34+ Cells
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.